Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities

Leukemia

Volumn 12, Issue 5, 1998, Pages 840-844

  Seeker Walker, L M ^a   Moorman, A V ^a   Bain, B J ^b   Mehta, A B ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

11q23; Alkylating agents; Anthracyclins; Epipodophylotoxins; Hematological malignancy; Secondary; Treatment related

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; EPIPODOPHYLLOTOXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HUMAN; INFANT; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SECOND CANCER;

EID: 0031945625     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401021     Document Type: Conference Paper

References (27)

1. Aplan PD, Chervinsky DS, Stanulla M, Burhans WC. Site-specific DNA cleavage within the MIL breakpoint cluster region induced by topoisomerase II inhibitors (see comments). Blood 1996; 87: 2649-2658.
2. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Duagaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L, Osterlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
3. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich, D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O, Rachmilewitz EA. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88: 4296-4303.
4. Hunger SP, Tkachuk DC, Amylon MD, Link MP, Carroll AJ, Welborn JL, Willman CL, Cleary ML. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood 1993; 81: 3197-3203.
5. Kingma PS, Greider CA, Osheroff N. Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 1997; 36: 5934-5939.
6. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
7. Domer PH, Head DR, Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995; 9: 1305-1312..
8. Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillière's Clin Haematol 1996; 9: 57-85.
9. Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Philip P, Diaz MO, Rowley JD. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993; 82: 3705-3711.
10. Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 1994; 8: 2174-2178.
11. Goto H, Shimazaki C, Tatsumi T, Yamagata N, Inaba T, Fujita N, Moriguchi T, Yamamoto K, Seto M, Ueda R. Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide? Int J Hematol 1994; 60: 145-149 (Abstr.).
12. Kubota M, Hoshino Y, Doi H, Ueno H, Nishida Y, Hirota H, Akiyama Y. Myelodysplastic syndrome with t(9;11)(p22;q23) after treatment for B-cell acute lymphoblastic leukemia without epipodophyllotoxins. Acta Haematol 1994; 92: 33-35.
13. Sandoval C, Head DR, Mirro J Jr, Behm FG, Ayers CD, Raimonoi SC. Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia. Leukemia 1992; 6: 513-519.
14. Felix CA, Hosler MR, Winick NJ, Masterson M, Wilson A, Lange BJ. ALL-1 gene rearrangements in DNA topoisomerase U inhibitor-related leukemia in children. Blood 1995; 85: 3250-3256.
15. Sandoval C, Pui C, Bowman LC, Heaton DC, Hurwitz CA, Raimondi S, Behm F, Head D. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993; 11: 1039-1045.
16. Zhang Y, Poetsch M, Weber-Matthiesen K, Rohde K, Winkemann M, Haferlach T, Gassmann W, Ludwig WD, Grote W, Loffler H, Schlegelberger B. Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies. Br J Haematol 1996; 92: 673-680.
17. Blutters-Sawatzki R, Borkhardt A, Grathwohl J, Repp R, RheinischBecker I, Bohle RM, Lamport F. Secondary acute myeloid leukemia with translocation (4;11) and MLL/AF4 rearrangement in a 15-year-old boy treated for common acute lymphoblastic leukemia 11 years earlier. Ann Hematol 1995; 70: 31-35.
18. Seeker-Walker LM, Stewart EL, Todd A. Acute lymphoblastic leukaemia with t(4;11) follows neuroblastoma: a late effect of treatment? Med Pediatr Oncol 1985; 13: 48-50.
19. Auxenfants E, Morel P, Lai JL, Sartiaux C, Detourmignies L, Bauters F, Fenaux P. Secondary acute lymphoblastic leukemia with t(4;11): report on two cases and review of the literature. Ann Hematol 1992; 65: 143-146.
20. Pedersen-Bjergaard J. Acute lymphoid leukemia with t(4;11)(q21;q23) following chemotherapy with cytostatic agents targeting at DNA-topoisomerase II (editorial). Leukemia Res 1992; 16: 733-735.
21. Lennard A, Jackson GH, Carey PJ, Bown N, Middleton P, Proctor SJ. Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease: case report and review of the literature. Leukemia 1991; 5: 624-627.
22. Narayanan MM, Morgenstern GR, Chang JC, Harrison CJ, Ranson M, Scarffe JH. Acute lymphoblastic leukaemia following Hodgkin's disease is associated with a good prognosis. Br J Haematol 1994; 86: 867-869.
23. Prieto F, Palau F, Badia L, Beneyto M, Perez-Sirvent ML, Orts A, Castel V. 11q23 abnormalities in children with acute nonlymphocytic leukemia (M4-M5). Association with previous chemotherapy. Cancer Genet Cytogenet 1990; 45: 1-11.
24. Hudson MM, Raimondi SC, Behm FG, Pui CH. Childhood acute leukemia with 1(11;19) (q23;p13). Leukemia 1991; 5: 1064-1068.
25. Huret JL, Brizard A, Slater R, Charrin C, Bertheas MF, Guilhot F, Kroes W, van Leeuwen E, Schoot EV et al. Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients - updated published cases and 16 new observations (review). Leukemia 1993; 7: 152-160.
26. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett, NA, Borrow J, Zeleznik-Le N. All patients with the T(11;16)(q23;p13.3) that involves MIL and CBP have treatmentrelated hematologic disorders. Blood 1997; 90: 535-541.
27. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997; 89: 3945-3950.